Skip to Content
Stanford Medicine Dermatology

Stanford Medicine

Explore Stanford Medicine

  • Health Care
    • Find a doctor

    • Adult-care doctor
    • Pediatrician or pediatric specialist
    • Obstetrician
    • Clinics & Services

    • Adult care
    • Pediatric care
    • Obstetrics
    • Clinical trials
    • Locations

    • Stanford Health Care
    • Stanford Children's Health
    • Emergency Department
    • Dial 911 in the event of a medical emergency

    Explore Health Care

    Learn how we are healing patients through science & compassion

    Back
  • Research
    • Basic science departments
    • Clinical science departments
    • Institutes
    • Research centers
    • See full directory
    • Research Resources

    • Research administration
    • Academic profiles
    • Clinical trials
    • Funding opportunities
    • See all
    • Professional Training

    • Postdoctoral scholars
    • Clinical research fellows

    Research News

    Neuroscientist Michelle Monje awarded MacArthur 'genius grant'

    Neuroscientist Michelle Monje awarded MacArthur 'genius grant'

    Explore Research

    Learn how we are fueling innovation

    Back
  • Education
    • MD program
    • PA Programs
    • PhD programs
    • Masters programs
    • Continuing Medical Education
    • Postdoctoral scholars
    • Residencies & fellowships
    • High School & Undergraduate Programs
    • See all
    • Education Resources

    • Academic profiles
    • School Administration
    • Basic science departments
    • Clinical science departments
    • Alumni services
    • Faculty resources
    • Diversity programs
    • Lane Library
    • Student resources

    Education News

    Alice L. Walton School of Medicine and Stanford Medicine host AI conference on community health

    Alice L. Walton School of Medicine and Stanford Medicine host AI conference on community health

    Explore Education

    Learn how we empower tomorrow's leaders

    Back
  • Give

    Support Stanford Medicine

    • Support teaching, research, and patient care.

    • Ways to give
    • Why giving matters
    • Make a gift online

    Support Children's Health

    • Support Lucile Packard Children's Hospital Stanford and child and maternal health

    • Ways to give
    • How your gift helps
    • Make an online gift
    Back
  • About
    • About us
    • News
    • Contacts
    • Maps & directions
    • Leadership
    • Vision
    • Diversity
    • Global health
    • Community engagement
    • Events
    • How you can help

    Stanford School of Medicine

    Stanford Health Care

    Stanford Children's Health

    Back
  • Site Search
  • Faculty

    Faculty

    • All Affiliated Faculty
    • Open Faculty Positions
  • Education

    Education

    • Residency

      Residency

      • Message from Program Directors
      • Residency Program Leadership
      • Research and Elective Opportunities
      • Subspecialties
      • Curriculum
      • Residents
      • Resident Life
      • Resident Wellness
      • Application Process
      • Resources
      • Global Health
      • Clinical Sites
      • Salary & Benefits
    • Medical Students
    • Fellowship

      Fellowship

      • Post-Doctoral Research Fellowship
      • Peds Research Fellowship
      • Melanoma-focused Research Fellowship
    • Visiting Rotations & Observerships
    • Grand Rounds

      Grand Rounds

      • Information for Patients
      • Information for Doctors
      • Directions
    • Rodan + Fields Lecture
    • COVID as a Catalyst Webinar
    • Marvin Karasek Lecture
  • Research

    Research

    • Stanford EB Research

      Stanford EB Research

      • Current Studies

        Current Studies

        • Genetic Testing for DEB
        • Serlopitant for Itch in EB
        • Characteristics of RDEB Patients
        • EB 101 for RDEB
        • Intravenous C7 for RDEB
        • Injected Gene Therapy for RDEB
        • Exon Skipping Therapy
        • EBCRC
        • RDEB Wound Natural History
        • Stanford and UMCG Cannabinoid Survey
        • Drug Repurposing
      • Prior Clinical Studies
      • Pre-Clinical Studies to Date
      • Meet the Clinical Research Team
      • Stanford EB Publications
      • In the Press
    • Clinical Trials
    • Skin Cancer Brochure
    • Epithelial Biology Program
    • Stanford EB Research

      Stanford EB Research

      • Current Studies

        Current Studies

        • Serlopitant for Itch in EB
        • Characteristics of RDEB Patients
        • EB 101 for RDEB
        • Intravenous C7 for RDEB
        • Topical Gene Therapy for RDEB
        • Injected Gene Therapy for RDEB
        • Exon Skipping Therapy
        • EBCRC
        • RDEB Wound Natural History
        • Stanford and UMCG Cannabinoid Survey
        • Drug Repurposing
      • Prior Clinical Studies
      • Pre-Clinical Studies to Date
      • Meet the Clinical Research Team
      • Stanford EB Publications
      • In the Press
    • Stanford Skin Innovation and Interventional Research Group
    • Translational AI in Dermatology (TRAIND)
  • Resources

    Resources

    • Department History
    • Photo Instruction for Video Visits
    • Epithelial Biology Program
    • Genetic Skin Disease Center

      Genetic Skin Disease Center

      • Epidermolysis Bullosa Clinic

        Epidermolysis Bullosa Clinic

        • EB FAQs
        • EB Clinic Visits
        • EB Wound Care Videos
        • EB Resources
        • EB People
      • Our Team
      • Clinic Appointments and Referrals
      • Support Our Research
      • Contact Us
    • In The Spotlight Archive
    • Related Links
    • Clinical Schedules
    • Newsletter
    • Resident On-Call Schedule
  • Patient Care

    Patient Care

    • All Clinics
    • Directions to SMOC
    • Subspecialties
  • Contact

    Contact

    • Administrative Staff
  • SUPPORT

Clinical Trials Unit

Stanford University School of Medicine's Center for Advanced Dermatologic Investigation is the Dermatology Department's clinical trials unit. 

The Center is home to 12-15 ongoing clinical studies, investigating the safety and efficacy of new and currently available drugs and over-the-counter medications.  The Center works with Stanford's own panel on medical research, leading pharmaceutical companies,and the Food and Drug Administration to safely and ethically expand the medical field's knowledge of dermatologic treatments.  New studies begin regularly, and the Center continues to recruit patients with skin aging, sun damage, skin cancer (including basal cell carcinomas), psoriasis, atopic dermatitis, rosacea, and other dermatologic diseases for ongoing studies. 

Skin Aging Studies

We seek to understand the human aging processes as it relates to skin on a fundamental level. To this end, our studies focus on clinical and translational research efforts ranging from: (1) the analysis of gene changes which predispose individuals to exceptionally youthful skin to (2) molecular signatures that may be biomarkers for aging skin to (3) the careful study of new candidate agents which might affect the skin aging process.

Nonmelanoma Skin Cancer

Recent advances in our understanding of basal cell skin cancer biology have enabled the development of cutting edge study drugs which combat tumor growth. We are currently home to a number of clinical trials at the forefront of potential therapy for advanced or metastatic basal cell cancer. In addition, we seek to understand the biology of basal cell skin cancers and to identify molecular predictors for treatment success.

Acne Rosecea

This is a common and frustrating chronic inflammatory condition of the face, usually affecting older individuals. The causes of this complex condition are the subject of much study. Our clinical studies seek to identify new topical or oral medications to improve the symptoms of acne rosacea.

Contact

For more information, please email dermtrials@stanford.edu

Featured Clinical Trials

No trials match your search ""

Psoriasis Clinical Trials

  • Diagnostic and Prognostic Biomarkers for High-impact Chronic Pain: Development and Validation

    To identify diagnostic and prognostic biomarker signatures of recovery versus having persisting high-impact chronic pain and functional disability in adults with Chronic Musculoskeletal Pain.

    Investigator

    • Sean Mackey, M.D., Ph.D.
    Now accepting new patients View Details
  • Generic Database of Very Low Birth Weight Infants

    The Generic Database (GDB) is a registry of very low birth weight infants born alive in NICHD Neonatal Research Network (NRN) centers. The GDB collects observational baseline data on both mothers and infants, and the therapies used and outcomes of the infants. The information collected is not specific to a disease or treatment (i.e., it is "generic"). Data are analyzed to find associations and trends between baseline information, treatments, and infant outcome, and to develop future NRN trials.

    Investigator

    • Krisa Van Meurs
    Now accepting new patients View Details
  • Natural History Evaluation of Charcot Marie Tooth Disease (CMT) Types CMT1B, CMT2A, CMT4A, CMT4C, and Others

    This is an observational longitudinal study to determine the natural history and genotype-phenotype correlations of disease causing mutations in Charcot Marie Tooth disease (CMT) type 1B (CMT1B), 2A (CMT2A), 4A (CMT4A), and 4C (CMT4C).

    The investigators will also be determine the capability of the newly developed CMT Pediatric Scale (CMT Peds scale) and the Minimal Dataset to measure impairment and perform longitudinal measurements in patients with multiple forms of CMT over a five year window

    Investigator

    • John W. Day, MD, PhD
    Now accepting new patients View Details
  • Effects of Maintenance Cabozantinib+BSC Versus BSC in Children and AYA With Osteosarcoma

    The participants of this study will be children, adolescents, and young adults with residual osteosarcoma, which cannot be removed completely through surgery.

    Participants will have achieved a partial response or stable disease at the end of conventional chemotherapy. Osteosarcoma is cancer of the bone. The cancer cells make immature bone cells, known as osteoid.

    Osteosarcoma is very rare, but it is the most common type of bone cancer in children and teens. It is most common in teens and young adults.

    In this study, participants will receive either cabozantinib and best supportive care or the best supportive care alone. Best supportive care will be provided at the investigator's discretion and according to institutional guidelines.

    It includes antibiotics, nutritional support, correction of metabolic disorders, optimal symptom control and pain management (including radiotherapy), etc. but does not include tumor specific therapy.

    Cabozantinib will be taken by mouth (orally), as a tablet, once a day. Cabozantinib will be provided to participants who tolerate it for as long as their disease does not progress. Participants in the study receiving best supportive care alone may switch to treatment with cabozantinib and best supportive care if their disease progresses and if other eligibility criteria are met.

    Participants may withdraw consent to participate at any time.

    The estimated duration of the study for participants is 24 months, however a participant could remain in the study longer if demonstrating treatment benefit.

    Now accepting new patients View Details
  • Electrical Stimulation for the Treatment of Optic Neuropathies

    The overall aim of this study is to see whether long-term electrical stimulation with a home-stimulation device works well and is safe for the treatment of open-angle glaucoma. Open-Angle Glaucoma is a disease where the nerves in the back of your eye die off faster than expected regardless of your eye pressure.

    Investigator

    • Jeffrey Goldberg, MD, PhD
    Now accepting new patients View Details
  • Developing Tools for Dialysis Decision Support

    The aim of this study is to evaluate the impact of a web-based dialysis decision support tool on decisional conflict, and values-treatment concordance and other decisional outcomes in individuals with advanced chronic kidney disease, and to assess the tool's acceptability and usability.

    Investigators

    • Margaret Yu
    • Manjula Kurella Tamura
    Now accepting new patients View Details
  • Establishing a Dose-response Relationship with Accelerated Transcranial Magnetic Stimulation

    This study evaluates an accelerated schedule of theta-burst stimulation using a transcranial magnetic stimulation device for treatment-resistant depression. In a double-blind, randomized, sham-controlled fashion, half the participants will receive accelerated theta-burst stimulation while half will receive sham treatment.

    Investigators

    • Nolan Williams
    • David Spiegel
    Now accepting new patients View Details
  • Gastroschisis Outcomes of Delivery (GOOD) Study

    The objective of this study is to investigate the hypothesis that delivery at 35 0/7- 35 6/7 weeks in stable patients with gastroschisis is superior to observation and expectant management with a goal of delivery at 38 0/7 - 38 6/7 weeks. To test this hypothesis, we will complete a randomized, prospective, multi-institutional trial across NAFTNet-affiliated institutions. Patients may be enrolled in the study any time prior to 33 weeks, but will be randomized at 33 weeks to delivery at 35 weeks or observation with a goal of 38 weeks. The primary composite outcome will include stillbirth, neonatal death prior to discharge, respiratory morbidity, and need for parenteral nutrition at 30 days.

    Investigator

    • Yair Blumenfeld, MD
    Now accepting new patients View Details
  • MHE3 Clinical Trial - Overcoming Obstacles

    The goal of this clinical trial is to increase and strengthen connections between Latinx individuals and mental health services. Through this intervention, the investigators aim to improve mental health literacy, decrease stigma, increase coping skills, and increase mental health help seeking, even before they are in crisis. Participants will be asked to participate in six educational sessions hosted by Promotores de Salud.

    Investigator

    • Jennifer A. Newberry
    Now accepting new patients View Details
  • Diabetes RElated to Acute Pancreatitis and Its Mechanisms

    The overriding objective of DREAM is to conduct a prospective longitudinal (36 months) observational clinical study to investigate the incidence, etiology, and pathophysiology of diabetes mellitus (DM) following acute pancreatitis (AP).

    Investigators

    • Vipul Sheth, MD, PhD
    • Marina Basina
    • Walter Park
    Now accepting new patients View Details
  • Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

    This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among premenopausal, early- stage breast cancer (EBC) patients with estrogen receptor (ER)-positive, HER2-negative tumors and 21-gene recurrence score (RS) between 16-25 (for pN0 patients) and 0-25 (for pN1 patients).

    Investigator

    • Irene Wapnir, MD
    Now accepting new patients View Details
  • LymphBridge: Surgical Evaluation for Breast Cancer-Associated Lymphedema (BioBridge)

    To investigate whether the addition of Fibralign's BioBridge® Collagen Matrix (BioBridge) devices to the standard surgery for vascularized lymph node transfer will improve the outcome of surgical treatment in lymphedema of the upper arm.

    Investigator

    • Dung Nguyen
    Now accepting new patients View Details
  • Electrical Stimulation for Continence After Spinal Cord Injury

    This study aims to improve continence and voiding of patients with spinal cord injury using electrical stimulation.

    The Finetech Vocare Bladder System is an implantable sacral nerve stimulator for improving bladder and bowel function in patients with spinal cord injury (SCI). It has been commercially available in Britain and other countries since 1982, and has been used in thousands of patients with SCI to improve bladder, bowel and sexual function. It received FDA approval in 1998 under Humanitarian Device Exemption H980005 and H980008 for providing urination on demand and to aid in bowel evacuation.

    Electrical stimulation to produce bladder contraction and improve bladder voiding after spinal cord injury has usually been combined with cutting of sensory nerves to reduce reflex contraction of the bladder, which improves continence. However, cutting these nerves has undesirable side effects. This study will not cut any sensory nerve. This study is testing the use of the stimulator for inhibiting bladder contraction by stimulating sensory nerves to improve continence after spinal cord injury, and for blocking sphincter contraction to improve voiding.

    Investigators

    • Graham Creasey
    • Harminder Singh, MD, MBA
    Now accepting new patients View Details
  • Long Term Effects On Recipients of Hematopoietic Stem Cell Transplantation

    This project allows for the systematic collection and analysis of long-term follow-up clinical parameters in children who have received a stem cell transplant. The data collected will assist in determining appropriate intervention and treatment plans for patients enrolled on this study. In addition, future patients may benefit by having the ability to anticipate problems and develop methods of prevention or early intervention.

    Investigators

    • Ami J. Shah
    • Kenneth Weinberg
    • Rajni Agarwal
    • Sharon E. Williams PhD
    Now accepting new patients View Details
  • Evaluation of Maralixibat in Pruritus Associated with General Cholestatic Liver Disease (EXPAND)

    The purpose of this study is to determine whether the investigational treatment (maralixibat) is safe and effective in pediatric and adult participants who have cholestatic liver disease with pruritus that has been refractory to other therapies, and who have no other treatment options.

    Investigator

    • Noelle Hanako Ebel
    Now accepting new patients View Details
  • Can Nitrous Oxide (Laughing Gas) be Used as a Sedative for GI Endoscopy Procedures?

    Nitrous oxide (commonly known as 'laughing gas') is often used during dental and other outpatient procedures, because it is easy to administer, is short-acting and rapidly clears from the body following the procedure.

    The investigators hypothesize that use of Nitrous oxide during GI endoscopy may enhance patient comfort during the procedure and speed-up post-procedure recovery, while minimizing the fatigue and mental fogginess some patients report the day after receiving standard sedative and narcotic drugs used routinely for the procedure.

    The investigators are interested in determining if adding Nitrous Oxide to commonly used sedation drugs will decrease fatigue, mental fogginess, and nausea/vomiting, as well as determine when the patient felt fully recovered from the effects of all sedatives given for the procedure.

    Investigator

    • Timothy Angelotti MD, PhD
    Now accepting new patients View Details
  • Clinical Feasibility and Evaluation of Silicon Photon Counting CT

    The purpose of the study is to collect data to evaluate utility of the using photon-counting CT in a clinical setting.

    Investigator

    • Adam Wang
    Now accepting new patients View Details
  • Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD

    Efficacy, Safety, and Tolerability of two administrations of COMP360 in participants with treatment-resistant depression (TRD)

    Investigator

    • Jason Tucciarone, MD, PhD
    Now accepting new patients View Details
  • Evaluate Safety of Axicabtagene Ciloleucel Reinfusion (Axi-Cel-2) in Patients With Relapsed and/or Refractory Second Line High-Risk Non-Hodgkin Lymphoma After Standard of Care Axi-Cel

    This is a phase Ib study to establish safety of Axi-Cel-2 in patients with Large B Cell Lymphoma (LBCL) who are at high risk of relapse.

    Investigators

    • Melody Smith, MD, MS
    • Matthew Frank
    • Lori Muffly
    • Saurabh Dahiya, MD, FACP
    • Judith Shizuru
    • Robert Negrin
    • David Miklos
    Now accepting new patients View Details
  • International REgistry of COnservative or Radical Treatment of Localized Kidney Tumors

    Partial nephrectomy (PN) is the standard treatment for localized renal masses and should be preferred in clinical T1 (\<7 cm tumor diameter) renal tumors over radical nephrectomy (RN) whenever technically feasible. Nonetheless, indications, approaches, techniques for PN, and correct reporting of outcomes, are still a matter of great debate within the urology community. Concurrently, case-report series suggested that alternative strategies for the treatment of localized renal tumors (ablation techniques (AT), watchful waiting (WW), active surveillance (AS)) could be feasible with acceptable oncologic outcomes in particular settings of patients with localized renal tumors. In this complex clinical scenario, the role surgeon-related and environmental factors (such as surgical experience, hospital resources, countries' social background and performance of health system) are important to address the best personalized approach in patients with renal tumors.

    In the light of current evidence, many unsolved questions still remain and many unmet needs must be addressed. In particular, 1) the risk-benefit trade-offs between PN and RN for anatomically complex renal localized tumors; 2) the definition of evidence-based strategies to tailor the management strategy (AT vs WW vs AS vs surgery) in different subset of patients with particular clinical conditions (i.e. old, frail, comorbid patients); and 3) the definition of evidence-based recommendations to adapt surgical approach (open vs laparoscopic vs robotic) and resection techniques to different patient-, tumor-, and surgeon-specific characteristics.

    To meet the challenges, to overcome the limitations of current kidney cancer literature (such as the retrospective study design, potential risk of biases, and heterogeneous follow-up of most series), and to provide high-quality evidence for future development of effective clinical practice Guidelines, we designed the international REgistry of COnservative or Radical treatment of localized kiDney tumors (i-RECORD) Project.

    The expected impact of the i-RECORD project is to provide robust evidence on the leading clinical and environmental factors driving selection of the management strategy in patients with kidney cancer, and the differential impact of different management strategies (including AS, WW, AT, PN and RN) on functional, perioperative and oncological outcomes, as well as quality of life assessment, at a mid-long term follow-up (5-10 years).

    Investigator

    • Benjamin I. Chung
    Now accepting new patients View Details
  • Previous
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • Next

Dermatology Clinical Trials

  • HIIT Vs. MICT Training Study

    The purpose of this study is to compare the impact of high-intensity interval training (HIIT) versus moderate-intensity continuous training (MICT) on human health outcomes in healthy sedentary subjects, over 12 weeks of exercise training.

    The investigators will compare several health parameters, such as changes in multiomics profile, cardiorespiratory fitness, muscle strength, and body composition, before and after 12-week interventions of either HIIT or MICT.

    Investigator

    • Malene Lindholm
    Now accepting new patients View Details
  • KYSA-1: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis

    A Study of Anti-CD19 Chimeric Antigen Receptor T Cell Therapy for Subjects With Refractory Lupus Nephritis

    Investigator

    • Richard Lafayette
    Now accepting new patients View Details
  • International Collaborative Gaucher Group (ICGG) Gaucher Disease Registry & Pregnancy Sub-registry

    The ICGG Gaucher Registry is an ongoing, international multi-center, strictly observational program that tracks the routine clinical outcomes for patients with Gaucher disease, irrespective of treatment status. No experimental intervention is involved; patients in the Registry undergo clinical assessments and receive care as determined by the patient's treating physician.

    The objectives of the Registry are:

    * To enhance understanding of the variability, progression, identification, and natural history of Gaucher disease, with the ultimate goal of better guiding and assessing therapeutic intervention.* To assist the Gaucher medical community with the development of recommendations for monitoring patients, and to provide reports on patient outcomes, to optimize patient care.* To characterize the Gaucher disease population.* To evaluate the long-term effectiveness of imiglucerase and of eliglustat.

    Gaucher Pregnancy Sub-registry: The primary objective of this Sub-registry is to track pregnancy outcomes, including complications and infant growth, in all women with Gaucher disease during pregnancy, regardless of whether they receive disease-specific therapy. No experimental intervention is given; thus a patient will undergo clinical assessments and receive standard of care treatment as determined by the patient's physician.If a patient consents to this Sub-registry, information about the patient's medical and obstetric history, pregnancy, and birth will be collected, and, if a patient consents to data collection for her infant, data on infant growth through month 36 postpartum will be collected.

    Investigator

    • Gregory Enns
    Now accepting new patients View Details
  • Descemet Endothelial Thickness Comparison Trial II

    Descemet Endothelial Thickness Comparison Trial (DETECT) II is a multi-center, outcome assessor-masked, placebo-controlled clinical trial randomizing 60 patients with Fuchs endothelial dystrophy to DMEK versus Descemet Stripping Only (DSO) with adjunctive Ripasudil.

    Investigators

    • Jennifer Rose-Nussbaumer
    • Charles C. Lin, MD
    Now accepting new patients View Details
  • Diagnostic and Prognostic Biomarkers for High-impact Chronic Pain: Development and Validation

    To identify diagnostic and prognostic biomarker signatures of recovery versus having persisting high-impact chronic pain and functional disability in adults with Chronic Musculoskeletal Pain.

    Investigator

    • Sean Mackey, M.D., Ph.D.
    Now accepting new patients View Details
  • (HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis

    This is a randomized, double-blind, placebo-controlled, Phase 2/3 study comparing the efficacy and safety of elenestinib (BLU-263) + best supportive care (BSC) with placebo + BSC in patients with indolent systemic mastocytosis (ISM) whose symptoms are not adequately controlled by BSC. Parts 1 and 2 will enroll patients with ISM. Patients enrolled in Part 1 or Part 2 will roll over onto Part 3 to receive treatment with elenestinib in an open-label fashion following completion of the earlier Part. Part M will enroll patients with monoclonal mast cell activation syndrome (mMCAS). Part S will enroll participants with smoldering systemic mastocytosis (SSM). The study also includes PK groups that will enroll patients with ISM.

    Now accepting new patients View Details
  • Comparing Operative vs Non Operative Treatment for Pilonidal Disease

    The goal is to evaluate whether surgical excision of the pilonidal disease is needed after resolution of the initial symptoms when the patient follows regular hair removal regimen such as laser epilation.

    Investigator

    • Bill Chiu
    Now accepting new patients View Details
  • Evaluation of a Mixed Meal Test for Diagnosis and Characterization and Type 3c Diabetes Mellitus Secondary to Pancreatic Cancer and Chronic Pancreatitis (DETECT)

    The Coordinating and Data Management Center (CDMC) at MD Anderson Cancer will be responsible for the coordination and data management for the Evaluation of a mixed meal test for Diagnosis and characterization of Type 3c diabetes mellitus secondary to pancreatic cancer and chronic pancreatitis (DETECT), which is part of the NIH U01 funded Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer (CPDPC). Similar to all studies that will be coordinated and managed by the CDMC, no patient enrollment will occur at MDACC. All patient recruitment will occur at external sites that are a part of the CPDPC, which are listed in the appended DETECT protocol. The data management systems, auditing, and monitoring effort are supported by the CDMC.

    Investigator

    • Walter Park
    Now accepting new patients View Details
  • Evaluating Pulse Oximetry Bias in Children With Darker Skin Pigmentation

    In this prospective study, the investigators will enroll 154 children with arterial lines to determine the accuracy of pulse oximeters in children with darker skin pigmentation. Studies in adults suggest pulse oximeters may overestimate the true level of oxygenation in the blood as measured directly by co-oximetry. However, pediatric data are relatively limited. This study, which is funded by the FDA through the Stanford-UCSF (University of California San Francisco) Clinical Excellence in Regulatory Science and Innovation (CERSI) Program, will determine if the error/bias is associated with skin pigmentation and whether the error falls outside FDA standards. The broader purpose of the study is to work toward eliminating health disparities.

    Investigator

    • Greg Adamson
    Now accepting new patients View Details
  • Efficacy of Nitrous Oxide in OCD: Pilot Study

    This study investigates whether the commonly used and well-tolerated inhaled anesthetic nitrous oxide can rapidly improve symptoms of OCD.

    Investigators

    • Carolyn Rodriguez
    • Peter Johannes van Roessel
    Now accepting new patients View Details
  • Developing Tools for Dialysis Decision Support

    The aim of this study is to evaluate the impact of a web-based dialysis decision support tool on decisional conflict, and values-treatment concordance and other decisional outcomes in individuals with advanced chronic kidney disease, and to assess the tool's acceptability and usability.

    Investigators

    • Margaret Yu
    • Manjula Kurella Tamura
    Now accepting new patients View Details
  • Diabetes RElated to Acute Pancreatitis and Its Mechanisms: Metabolic Outcomes Using Novel CGM Metrics

    The DREAM-ON study will investigate whether continuous glucose monitoring (CGM) is useful to predict risk for developing diabetes mellitus (DM) and pre-diabetes mellitus (PDM), the need for insulin therapy among those who develop DM, and to determine whether CGM can provide insight into the pathophysiology and DM subtype among participants who have experienced an episode of acute pancreatitis (AP). Thus, the results of the DREAM-ON study could inform future clinical practice guidelines for the management AP as well as potentially extending the licensing authorization for CGM to include use in patients with pancreatogenic (Type 3c) DM.

    Investigator

    • Walter Park
    Now accepting new patients View Details
  • Establishing a Dose-response Relationship with Accelerated Transcranial Magnetic Stimulation

    This study evaluates an accelerated schedule of theta-burst stimulation using a transcranial magnetic stimulation device for treatment-resistant depression. In a double-blind, randomized, sham-controlled fashion, half the participants will receive accelerated theta-burst stimulation while half will receive sham treatment.

    Investigators

    • Nolan Williams
    • David Spiegel
    Now accepting new patients View Details
  • Evaluating Cryopreserved Osteochondral Allograft Cores for the Treatment of Osteochondral Lesions in the Knee

    The primary objective of this study is to obtain evidence of the effectiveness of Cryopreserved Osteochondral Allograft Core in the treatment of osteochondral lesions on the femoral condyle.

    Investigator

    • Seth Lawrence Sherman, MD
    Now accepting new patients View Details
  • Gastroschisis Outcomes of Delivery (GOOD) Study

    The objective of this study is to investigate the hypothesis that delivery at 35 0/7- 35 6/7 weeks in stable patients with gastroschisis is superior to observation and expectant management with a goal of delivery at 38 0/7 - 38 6/7 weeks. To test this hypothesis, we will complete a randomized, prospective, multi-institutional trial across NAFTNet-affiliated institutions. Patients may be enrolled in the study any time prior to 33 weeks, but will be randomized at 33 weeks to delivery at 35 weeks or observation with a goal of 38 weeks. The primary composite outcome will include stillbirth, neonatal death prior to discharge, respiratory morbidity, and need for parenteral nutrition at 30 days.

    Investigator

    • Yair Blumenfeld, MD
    Now accepting new patients View Details
  • HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide

    This is a prospective, multi-center, Phase II study of hematopoietic cell transplantation (HCT) using human leukocyte antigen (HLA)-mismatched unrelated donors (MMUD) for peripheral blood stem cell transplant in adults and bone marrow stem cell transplant in children. Post-transplant cyclophosphamide (PTCy), tacrolimus and mycophenolate mofetil (MMF) will be used for for graft versus host disease (GVHD) prophylaxis. This trial will study how well this treatment works in patients with hematologic malignancies.

    Now accepting new patients View Details
  • Edwards PASCAL CLASP IID/IIF Pivotal Clinical Trial

    To establish the safety and effectiveness of the Edwards PASCAL Transcatheter Valve Repair System in patients with degenerative mitral regurgitation (DMR) who have been determined to be at prohibitive risk for mitral valve surgery by the Heart Team, and in patients with functional mitral regurgitation (FMR) on guideline directed medical therapy (GDMT)

    Investigators

    • Jack Boyd
    • Albert Cheung
    • Christiane Haeffele
    • William Hiesinger, MD
    • Rahul P Sharma, MBBS, FRACP
    • Yasuhiro Shudo, MD, PhD
    • David Lee, MD
    • William Fearon, MD
    Now accepting new patients View Details
  • GD2 CAR T Cells in Diffuse Intrinsic Pontine Gliomas(DIPG) & Spinal Diffuse Midline Glioma(DMG)

    The primary purpose of this study is to test whether GD2-CAR T cells can be successfully made from immune cells collected from children and young adults with H3K27M-mutant diffuse intrinsic pontine glioma (DIPG) or spinal H3K27M-mutant diffuse midline glioma (DMG). H3K27Mmutant testing will occur as part of standard of care prior to enrollment.

    Investigators

    • Katherine Jane Ryan
    • Crystal Mackall
    • Laura Prolo
    • Lindsey Rasmussen
    • Timothy Thomas Cornell
    • Sneha Ramakrishna
    • Sonia Partap
    • Paul Graham Fisher, MD
    • Kara Davis
    • Michelle Monje
    • Susan Hiniker
    Now accepting new patients View Details
  • Examining Mu Opioid Mechanisms of Ketamine's Rapid Effects in OCD (MKET2)

    The purpose of this study is to understand how ketamine works in the brain to bring about a reduction in OCD symptoms.

    Investigator

    • Carolyn Rodriguez
    Now accepting new patients View Details
  • Cool Prime Comparative Effectiveness Study for Mild HIE

    To determine effectiveness of therapy to improve neurodevelopmental outcomes in infants with mild HIE. To determine the adverse effects of Therapeutic Hypothermia (TH) in mild HIE on the neonate and his/her family. Determine heterogeneity of the treatment effect across key subgroups obtained in the first 6 hours after birth prior to the decision to initiate therapy.

    Investigators

    • Susan R. Hintz, M.D., M.S. Epi.
    • Krisa Van Meurs
    Now accepting new patients View Details
  • Previous
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • Next

Pediatric Dermatology Clinical Trials

No trials match your search ""

No trials match your search ""

No trials match your search ""

On this page

On this page

Ongoing & Upcoming Studies

Ongoing Studies

Upcoming Studies

Dermatology

Stanford Medicine

News

Careers

Contact

Health Care

Stanford Health Care

Stanford Children's Health

Stanford School of Medicine

About

Contact

Maps & Directions

Careers

Basic Science Departments

Clinical Science Departments

Academic Programs

Vision

Find People
Visit Stanford
Search Clinical Trials
Give a Gift
©2025 Stanford University
  • Privacy Policy
  • Terms of Use
  • Accessibility
  • See us on Facebook
  • See us on X (Twitter)
  • Stanford University
  • Stanford School of Medicine
  • Stanford Health Care
  • Stanford Children's Health
  • Stanford Health Care Tri-Valley
  • Stanford Medicine Partners